Leading Diagnostic INNOVATION

GeneproDX offers an exciting investment opportunity through ThyroidPrint®, an innovative cancer diagnostic product developed in partnership with Biocartis®. ThyroidPrint® unique decentralized model enables global accessibility, addressing the critical need for rapid and accurate thyroid nodule diagnosis. This positions GeneproDX as a promising player in the future of healthcare investment.

What makes us UNIQUE

Our decentralized model, enabled by the Idylla™ Platform, allows tests to be performed in just 3 hours in more than countries.

Market Access across five continents, including USA

The market: a global opportunity of US $ 1.8 B per year

ThyroidPrint®, as the first and currently the only test for Indeterminate Thyroid Nodules (ITN) available in EU and LATAM, is paving the way in a market worth $1.8 billion annually. Our strategic plan involves consolidating our leadership in LATAM and the EU. Additionally, we will expand into Asia and the Middle East in 2024, before entering the U.S. market in 2025, and then Canada and Oceania during 2026.

Three key facts

1.25 M thyroid FNA

Annually 1.25 M thyroid FNA biopsies are reported as indeterminate. In ITN, the risk of cancer is 25%, therefore surgery is recommended in most cases.

900K unnecessary surgeries

Approximately, 3 out of 4 surgeries for ITN are benign, resulting in an unacceptably high rate of unnecessary surgeries (900k/year globally)

Saving $1.26 billion per year

In the US, unnecessary ITN surgeries cost the health system approximately US $1.26 B/year*

Steering Precision Medicine

The experienced leadership team, advisors and board members who are guiding GeneproDX vision and ensuring our innovative approach to precision medicine reaches every corner of the globe.

Executive Team

Hernan Gonzalez MD, PhD Founder, CEO &
Board Member

Professor of Surgery P. Universidad Católica de Chile
Santiago, Chile

Carlos López, MBA
Executive VP
‍‍

Global Strategy & Operations
Barcelona, Spain

Natalia Mena, PhD, MBA
VP of LATAM
‍

LATAM Business Development an Sales
Santiago, Chile

Nicolás Droppelman MD
Clinical Advisor

Chief of the Division of Surgery
University of Los Andes
Santiago - Chile

Chris Holsinger, MD
Clinical Advisor

Chief Division Head & Surgery
Stanford University
Palo Alto, CA

Daniel Maestro, MBA
Managing Director Europe

Operations & Marketing
Barcelona, Spain

Board

Katherine Tynan, PhD
Board Member
‍

Business Strategy Advisor
San Francisco, CA

Rolando Brawer, PhD, MBA Board Member
‍

EVP, Strategy & Corporate Development at Berkeley Lights
San Diego, CA

Rodrigo Guerrero
‍Board Member
‍

CEO at Family Office Girona Investment Miami, Florida

Pablo Fernández
‍Board Member
‍

General Partner at Fondo Alerce Venture Capital
Santiago, Chile

Hernan Gonzalez MD, PhD Founder, CEO & Board Member

Professor of Surgery P. Universidad Católica de Chile
Santiago, Chile

Invest in GeneproDX and change the future

Leading Diagnostic INNOVATION

What makes us UNIQUE

The market: a global opportunity of US $ 1.8 B per year

Three key facts

1.25 M thyroid FNA

900K unnecessary surgeries

Saving $1.26 billion per year

Predicts Benign Nodules
95%

Avoids Unnecessary Surgery
70%

Diagnostic Platform
‍qPCR

Number Biomakers
10

Time Around Time
‍1 - 7 days

Current Regions
Latin America / Europe

Steering Precision Medicine

Investing in GeneproDX means expediting the evolution of precision diagnostics, avoiding unnecessary invasive procedures by accurately ruling out cancer with our groundbreaking ThyroidPrint® technology

Contact us any time

Contact us for more information or to arrange a meeting.
Let's shape the future of precision medicine together.

Invest in GeneproDX and change the future

Leading Diagnostic INNOVATION

What makes us UNIQUE

The market: a global opportunity of US $ 1.8 B per year

Three key facts

1.25 M thyroid FNA

900K unnecessary surgeries

Saving $1.26 billion per year

Predicts Benign Nodules95%

Avoids Unnecessary Surgery70%

Diagnostic Platform‍qPCR

Number Biomakers10

Time Around Time‍1 - 7 days

Current Regions Latin America / Europe

Steering Precision Medicine

Investing in GeneproDX means expediting the evolution of precision diagnostics, avoiding unnecessary invasive procedures by accurately ruling out cancer with our groundbreaking ThyroidPrint® technology

Contact us any time

Contact us for more information or to arrange a meeting. Let's shape the future of precision medicine together.

Predicts Benign Nodules
95%

Avoids Unnecessary Surgery
70%

Diagnostic Platform
‍qPCR

Number Biomakers
10

Time Around Time
‍1 - 7 days

Current Regions
Latin America / Europe

Contact us for more information or to arrange a meeting.
Let's shape the future of precision medicine together.